{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:14Z","timestamp":1786119314913,"version":"build-2736575974"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1097\/mcp.0b013e328331805b","type":"journal-article","created":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T03:17:47Z","timestamp":1254367067000},"page":"604-610","source":"Crossref","is-referenced-by-count":4,"title":["Update on new pulmonary therapies"],"prefix":"10.1097","volume":"15","author":[{"given":"George Z","family":"Retsch-Bogart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210206","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1089\/hum.2007.022","article-title":"Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2b trial","volume":"18","author":"Moss","year":"2007","journal-title":"Hum Gene Ther"},{"key":"R2-13-20210206","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nbt1399","article-title":"CpG plasmids confer reduced inflammation and sustained pulmonary gene expression","volume":"26","author":"Hyde","year":"2008","journal-title":"Nat Biotechnol"},{"key":"R3-13-20210206","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.addr.2008.09.010","article-title":"Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy","volume":"61","author":"Griesenbach","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"R4-13-20210206","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(08)61168-X","article-title":"Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial","volume":"372","author":"Kerem","year":"2008","journal-title":"Lancet"},{"key":"R10-13-20210206","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ddmec.2007.09.001","article-title":"Cystic fibrosis: the mechanisms of pathogenesis of an inherited lung disorder","volume":"4","author":"Clunes","year":"2007","journal-title":"Drug Discov Today Dis Mech"},{"key":"R11-13-20210206","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpeds.2008.08.001","article-title":"Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis","volume":"154","author":"Sagel","year":"2009","journal-title":"J Pediatr"},{"key":"R12-13-20210206","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1164\/rccm.200804-551OC","article-title":"Lung function in infants with cystic fibrosis diagnosed by newborn screening","volume":"178","author":"Linnane","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R13-13-20210206","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1164\/rccm.200901-0069OC","article-title":"on behalf of AREST for Cystic Fibrosis (AREST-CF). Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening.","volume":"180","author":"Sly","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"R14-13-20210206","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa043891","article-title":"Mucus clearance and lung function in cystic fibrosis with hypertonic saline","volume":"354","author":"Donaldson","year":"2006","journal-title":"N Engl J Med"},{"key":"R15-13-20210206","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis","volume":"354","author":"Elkins","year":"2006","journal-title":"N Engl J Med"},{"key":"R16-13-20210206","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","article-title":"Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"176","author":"Flume","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"R17-13-20210206","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ppul.20603","article-title":"Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis","volume":"42","author":"Subbarao","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"R18-13-20210206","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/ppul.20909","article-title":"Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis","volume":"43","author":"Dellon","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"R20-13-20210206","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1378\/chest.07-2294","article-title":"Inhaled mannitol improves lung function in cystic fibrosis","volume":"133","author":"Jaques","year":"2008","journal-title":"Chest"},{"key":"R21-13-20210206","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/ppul.20903","article-title":"Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis","volume":"43","author":"Minasian","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"R24-13-20210206","first-page":"005087","article-title":"Sodium channel blockers for cystic fibrosis.","volume":"3CD","author":"Burrows","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R25-13-20210206","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1164\/rccm.200803-442OC","article-title":"Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in \u03b2ENaC-overexpressing mice","volume":"178","author":"Zhou","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R26-13-20210206","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1164\/rccm.200708-1233OC","article-title":"Development of chronic bronchitis and emphysema in \u03b2-epithelial Na+ channel-overexpressing mice","volume":"177","author":"Mall","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R28-13-20210206","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1124\/jpet.107.130443","article-title":"Pharmacological properties of 552-02, a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease","volume":"325","author":"Hirsh","year":"2008","journal-title":"J Pharmacol Exper Ther"},{"key":"R29-13-20210206","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12016-008-8081-2","article-title":"Anti-inflammatory therapies for cystic fibrosis-related lung disease","volume":"35","author":"Nichols","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"R30-13-20210206","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1183\/09031936.00146807","article-title":"Inhibition of airway proteases in cystic fibrosis lung disease","volume":"32","author":"Griese","year":"2008","journal-title":"Eur Respir J"},{"key":"R31-13-20210206","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1183\/09031936.00047306","article-title":"1-Antitypsin inhalation reduces airway inflammation in cystic fibrosis patients.","volume":"29","author":"Griese","year":"2007","journal-title":"Eur Respir J"},{"key":"R32-13-20210206","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJM199503303321303","article-title":"Effect of high-dose ibuprofen in patients with cystic fibrosis","volume":"332","author":"Konstan","year":"1995","journal-title":"N Engl J Med"},{"key":"R33-13-20210206","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jpeds.2007.04.009","article-title":"High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial","volume":"151","author":"Lands","year":"2007","journal-title":"J Pediatr"},{"key":"R34-13-20210206","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.200702-181OC","article-title":"Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis","volume":"176","author":"Konstan","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"R36-13-20210206","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0140-6736(91)91446-2","article-title":"Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment","volume":"338","author":"Valerius","year":"1991","journal-title":"Lancet"},{"key":"R37-13-20210206","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1183\/09031936.05.00009605","article-title":"Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients","volume":"26","author":"Tacetti","year":"2005","journal-title":"Eur Respir J"},{"key":"R38-13-20210206","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O","article-title":"Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis","volume":"23","author":"Frederiksen","year":"1998","journal-title":"Pediatr Pulmonol"},{"key":"R40-13-20210206","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cct.2009.01.003","article-title":"Early antipseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study","volume":"30","author":"Treggiari","year":"2009","journal-title":"Contemp Clin Trials"},{"key":"R41-13-20210206","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ppul.20873","article-title":"Shifting patterns of antibiotic use in cystic fibrosis","volume":"43","author":"Moskowitz","year":"2008","journal-title":"Pediatr Pulmnol"},{"key":"R42-13-20210206","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ppul.20429","article-title":"Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis","volume":"41","author":"Gibson","year":"2006","journal-title":"Pediatr Pulmonol"},{"key":"R43-13-20210206","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/ppul.20850","article-title":"Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project","volume":"43","author":"Coates","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"R44-13-20210206","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1569-1993(09)60109-0","article-title":"Effective treatment of chronic Pseudomonas aeruginosa (Pa) infection with tobramycin inhalation powder in cystic fibrosis patients","volume":"8","author":"Konstan","year":"2009","journal-title":"J Cyst Fibros"},{"key":"R45-13-20210206","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ppul.20736","article-title":"A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"43","author":"Retsch-Bogart","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"R46-13-20210206","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1378\/chest.08-1421","article-title":"Efficacy and safety of inhaled aztreonam lysine in cystic fibrosis","volume":"135","author":"Retsch-Bogart","year":"2009","journal-title":"Chest"},{"key":"R47-13-20210206","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.200712-1804OC","article-title":"Inhaled aztreonam lysine is effective in intensively-treated patients with cystic fibrosis","volume":"178","author":"McCoy","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R48-13-20210206","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimally important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"R49-13-20210206","first-page":"S28","article-title":"Effect of multiple courses of aztreonam lysine for inhalation (AZLI) on FEV1 and weight in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): analysis of 18-month data from CP-AI-006","volume":"8","author":"Oermann","year":"2009","journal-title":"J Cyst Fibros"},{"key":"R51-13-20210206","first-page":"320","article-title":"A phase 1 open label trial to assess the safety and tolerability of fosfomycin\/tobramycin for inhalation (FTI) in subjects with cystic fibrosis (CF) or bronchiectasis (BE).","volume":"S31","author":"Wilson","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"R52-13-20210206","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ppul.20966","article-title":"Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis","volume":"44","author":"Santos","year":"2009","journal-title":"Pediatr Pulmonol"}],"container-title":["Current Opinion in Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MCP.0b013e328331805b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:00:25Z","timestamp":1786039225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00063198-200911000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mcp.0b013e328331805b","relation":{},"ISSN":["1070-5287"],"issn-type":[{"value":"1070-5287","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}